307
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy

ORCID Icon, ORCID Icon, , ORCID Icon, , ORCID Icon, , , ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 1291-1298 | Received 14 Apr 2021, Accepted 23 Jun 2021, Published online: 18 Jul 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Giacomo Caldarola, A Chiricozzi, M Megna, P Dapavo, A Giunta, M Burlando, P Malagoli, V Dini, M Mariani, G Fabbrocini, P Quaglino, L Bianchi, A Parodi, K Peris & C De Simone. (2023) Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study. Expert Opinion on Biological Therapy 23:4, pages 365-370.
Read now

Articles from other publishers (3)

Teppei Hagino, Hidehisa Saeki & Naoko Kanda. (2023) Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis. Journal of Clinical Medicine 12:3, pages 974.
Crossref
Francesca PRIGNANO, Leonardo PESCITELLI, Emanuele TROVATO, Antonella DI CESARE, Aldo CUCCIA, Carlo MAZZATENTA, Michele PELLEGRINO, Franco MARSILI, Antonio CASTELLI, Luca BRANDINI, Maria C. NICCOLI, Franca TAVITI, Federica RICCERI, Salvatore PANDURI, Gionata BUGGIANI, Alberto GHILARDI, Pietro RUBEGNI, Marco ROMANELLI & Nicola PIMPINELLI. (2023) Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics. Italian Journal of Dermatology and Venereology 157:6.
Crossref
Giacomo Caldarola, Arianna Zangrilli, Nicoletta Bernardini, Mauro Bavetta, Clara De Simone, Dario Graceffa, Claudio Bonifati, Sara Faleri, Domenico Giordano, Marco Mariani, Adriana Micheli, Gaia Moretta, Gianluca Pagnanelli, Vincenzo Panasiti, Alessia Provini, Antonio Richetta, Ketty Peris & Luca Bianchi. (2022) Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study. Dermatologic Therapy 35:6.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.